News | February 23, 2024
Moderna posts Q4 2023 revenue at US$ 2.8 billion
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
We are achieving the target of developed India by making our young children healthy today
The project aims at screening the general health condition of the students enrolled in classes 6th to 12th.
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Subscribe To Our Newsletter & Stay Updated
